ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology-focused generative and agentic AI solutions, today announced the launch of its new Precision Suite™. This groundbreaking family of AI-powered solutions redefines the way life sciences and healthcare organizations achieve actionable insights, optimize clinical trials, accelerate in-market execution, and drive improved patient outcomes while saving millions in cost. Powered by ConcertAI's proprietary CARAai™ platform and the unparalleled depth of its integrated Oncology Data, the Precision Suite delivers rapid, persona-tailored insights and enterprise-wide value.
The Precision Suite leverages CARAai's multi-modal, AI-curated data architecture to translate complex medical and genomic data into precise, real-world applications. These applications are built on a unique platform that is comprised of assistants, agents, LLMs and LRMs that are specifically designed and trained to support use cases in life sciences and healthcare. Its seamless integration of diverse data types enables life sciences teams to respond faster, make evidence-backed decisions, and maximize strategic impact. At launch, the suite includes three powerful applications tailored to distinct use cases across the healthcare ecosystem.
Precision Explorer™ empowers Health Economics and Outcomes Research (HEOR), epidemiology, and medical teams to uncover actionable insights within minutes. Generative AI and intuitive interfaces streamline cohort creation, outcomes analysis, and hypothesis testing, unlocking insights 2x faster than traditional methods, saving customers millions. With its ability to leverage curated oncology data and align with industry guidelines, such as ASCO® Standards, Precision Explorer ensures high-quality, citation-backed results.
Precision Trials™ transforms clinical trial operations by enabling smarter, faster decisions in study design, site selection, and patient recruitment. Powered by dynamic AI agents, this solution reduces costly trial amendments, improves site performance, and ensures diversity and enrollment goals are met. CARAai's advanced data-processing capabilities provide real-time assessments, shortening trial timelines with the potential to deliver $4M+ in cost savings for Phase II and III studies.
Precision GTM™ focuses on commercialization strategies for oncology therapies, unifying fragmented clinical, claims, and social determinants of health data. Harnessing CARAai's multi-modal insights, this platform enables brand teams to track the real-time standard of care, physician trends, and treatment pathways. By accelerating decision-making and enabling timely engagement, Precision GTM empowers teams to achieve faster, more impactful market execution while generating up to $7M in value for a typical oncology brand.
Precision360™, the backbone of ConcertAI's Precision Suite™, integrates EMR and genomic data alongside claims and social determinants of health information to create a revolutionary new RWD dataset. With AI-curation and a recency of less than a week, it provides real-time access to actionable insights, eliminating delays in oncology research and decisions. Designed for speed and efficiency, Precision360 provides accuracy and reliability, even in complex, unstructured datasets.
'Precision Suite is a testament to our commitment to innovation and patient-first outcomes,' said Eron Kelly, CEO of ConcertAI. 'Its ability to process complex, diverse datasets in near real-time has allowed us to deliver immediately actionable insights that will save customers millions in costs, while accelerating their time to market for life saving therapeutics. These new SaaS products are all built on our CARAai platform, the leading agentic AI platform built specifically for the needs of the life sciences enterprise.'
'ConcertAI serves 75% of the top life science companies and more than 50% of the largest global healthcare providers,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This launch signifies the evolution of ConcertAI from providing specialized solutions to delivering enterprise-class SaaS tools. Precision Suite aligns our expertise with our mission to deliver scalable, impactful solutions that redefine what's possible in life sciences and healthcare today.'
Precision Explorer™ and Precision Trials™ will be available beginning June 30, 2025. Precision GTM™ will follow with availability by July 31, 2025. With these solutions, ConcertAI solidifies its position as the leader in generative and agentic AI tailored for oncology and broader life sciences applications.
About ConcertAI:
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article "Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial" reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, "Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation" describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, "A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier" reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: "It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. "The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. "We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases." Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: "These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation." About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030. View source version on Contacts EpiEndo Pharmaceuticals: Maria Bech, CEO+354 454 0090 Vigo Consulting (media relations):Rozi Morris+44 20 7390 0230epiendo@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Advanced Ceramics Market worth $16.27 billion by 2029, at 6.0%, says MarketsandMarkets™
Delray Beach, FL, June 11, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Advanced Ceramics Market is projected to reach USD 16.27 billion by 2029 from USD 12.16 billion in 2024, at a CAGR of 6.0%, as per the recent study by MarketsandMarkets™. The advanced ceramics market has grown robustly over the past few years due to numerous important factors. One of them is rising demand from industries such as electronics, automotive, aerospace, and the healthcare sector, which has given impetus to the growth of this market. Advanced ceramics, with their outstanding characteristics such as high-temperature resistance, strength, and electrical insulation, play a crucial role in producing components like semiconductors, engine components, and medical implants. For example, growth in electric cars and clean technologies has increased demand for ceramics used in batteries and power systems. Technological developments have played a key role to increase performance capabilities, such as corrosion resistance and strength of advanced ceramics, which qualify them for next-generation applications including 5G base stations and space missions. Download PDF Brochure: Browse in-depth TOC on 'Advanced Ceramics Market' 215 - Market Data Tables 54 – Figures 270 - Pages List of Key Players in Advanced Ceramics Market: KYOCERA Corporation (Japan) CeramTec (Germany) CoorsTek (US) Morgan Advanced Materials (UK) 3M (US), AGC Ceramics Co., Ltd. (Japan) MARUWA Co., Ltd. (Japan) Saint-Gobain Performance Ceramics & Refractories (France) Paul Rauschert GmbH & Co. KG. (Germany) Drivers, Opportunities and Challenges in Advanced Ceramics Market: Drivers: Government investments in research, energy, and aerospace & defense industries Restraint: Complex manufacturing processes of advanced ceramics Opportunity: Integration of nanotechnology in advanced ceramic materials Challenge: Brittleness of advanced ceramics Get Sample Pages: Key Findings of the Study: Alumina is projected to have the largest market share in 2024 in terms of value. Ceramic coatings application segment to have the second highest market share in the advanced ceramics market. Asia Pacific to be the largest market during the forecast period. Alumina ceramics has the largest share in terms of material in the advanced ceramics market. Alumina-based ceramics dominate most industrial segments like electronics, aerospace, and medical instruments. Due to their tolerance towards ultra-high temperature, alumina-based ceramics can effectively act as cutters, insulators, and substrates used in manufacturing semiconductor devices. The market for alumina ceramics has increased with the increasing demand for high-performance, long-lasting materials in miniaturized electronics and energy-efficient systems. With industries striving for sustainability, alumina ceramics also play their part by allowing longer-lasting components that minimize waste. In the advanced ceramics industry, their cost-effectiveness and versatility over other high-performance materials have made them a go-to option. Advancements in processing methods, including additive manufacturing, have further diversified their applications and enabled complex geometries and bespoke solutions. The market impact of alumina ceramics is reflected in their predicted growth, stimulated by growing investment in green energy and emerging manufacturing technologies. Ceramic matrix composites (CMCs) is a well-knowned applications in the advanced ceramics market, fueled by their superior properties and increasing uses in high-performance industries. In contrast to conventional ceramics, CMCs integrate ceramic fibers with a ceramic matrix, creating materials that possess greater strength, thermal resistance, and toughness while being lightweight. These properties make them more and more valuable in aerospace, automotive, and energy, where high tolerance to harsh environments is essential. In aerospace alone, for example, CMCs are changing engine parts with the ability to withstand temperatures well above 1,500°C, increasing fuel efficiency, and lowering emissions. This has fuelled demand and made CMCs a critical secondary keyword to the advanced ceramics market. The impact of CMCs on the market is significant since they overcome limitations of traditional materials such as metals and monolithic ceramics. Their thermal shock and wear resistance have increased their application in gas turbines, heat exchangers, and even medical implants, widening the application of the advanced ceramics market. Producers are spending big on research and development to maximize production processes, including chemical vapor infiltration and polymer infiltration pyrolysis, to increase output and lower costs. Get Customization on this Report: Europe commands the third-largest market share among the global advanced ceramics market on account of a mix of industrial strengths, technological capabilities, and multifarious applications across target sectors. The continent's resilient manufacturing sector, more so in nations such as Germany, France, and the UK, underpins strong demand for advanced ceramics. Germany has globally recognized automotive sector, which depends greatly on these materials for parts such as brakes, engine components, and exhaust systems because of their resistance to wear and heat. This industrial dominance is matched by Europe's dominance in aerospace and defense, where high-tech ceramics are valued for their lightness and resistance to harsh conditions, enabling innovations in aircraft and military hardware. Moreover, the emphasis of Europe on sustainability and renewable energy sources supports the market. Advanced ceramics are a central component in the generation of energy, for instance, in solar panels and wind turbines, that is consistent with the region's ambitious environmental agendas. Browse Adjacent Markets Ceramics and Glass Market Research Reports Related Reports: Sodium Silicate Market Gold Nanoparticles Market Advanced Ceramics Market Cyclic Olefin Polymer Market Heavy Construction Equipment Market CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website:
Yahoo
an hour ago
- Yahoo
Vision Marine Secures U.S. Battery Supply Chain Through Strategic Expansion with Octillion Power Systems
U.S.-Assembled 45.36 kWh High-Voltage Packs from Nevada Facility to Promote Accelerated OEM and Consumer Growth Through E-Motion™ Platform MONTREAL, QC / / June 11, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) ("Vision Marine" or the "Company"), a pioneer in high-voltage electric marine propulsion systems, today announced a major milestone in its U.S. scale-up strategy: the expansion of its longstanding partnership with Octillion Power Systems, a top-tier U.S.-based lithium-ion battery manufacturer, to produce Vision-branded high-voltage battery packs dedicated exclusively to the American market. Under the terms of the agreement, Octillion will assemble Vision Marine's new proprietary 45.36 kWh battery packs at its state-of-the-art facility in Nevada, aiding in fast, cost-efficient distribution across North America. These batteries are designed to support both Vision Marine's OEM integrations and consumer-facing electric boat offerings, delivering increased power, extended range, and improved performance-while reducing total system cost and simplifying logistics. This renewed and enhanced partnership establishes a partial U.S. supply chain for Vision Marine's proprietary E-Motion™ 180E electric outboard system, unlocking key efficiencies. In addition to supporting factory integration with third-party manufacturers, the partnership provides a reliable and consistent battery supply for Vision Marine's direct-to-consumer electric boat sales, including those produced under formal production agreements with multiple established boat manufacturers. These vessels are sold through Vision Marine's channels while retaining the original manufacturer's branding, enabling broad market reach without altering brand identity. "Octillion has been an integral technology partner to Vision Marine for several years, powering our most high-performance programs-including multiple electric world speed record boats," said Alexandre Mongeon, CEO of Vision Marine Technologies. "With this expanded partnership and the support of Octillion's Nevada facility, we are positioned to scale commercial deliveries and prepare for our next record-setting performance with more power and higher efficiency." Founded in 2009 and headquartered in California, Octillion Power Systems is a global leader in lithium-ion battery technology, with over 2 million battery systems deployed across electric vehicles, industrial equipment, and energy storage sectors. Octillion brings deep technical expertise and proven large-scale manufacturing capabilities-essential components to Vision Marine's growth roadmap. "Having collaborated with Vision Marine since 2021 on the development of this American-built, marine-dedicated battery platform has been both technically rewarding and strategically significant," said Paul Beach, President of Octillion Power Systems. "We are proud to manufacture these 45.36 kWh packs at our Nevada facility and to work in close alignment with Vision Marine's team as they scale delivery and continue to push the boundaries of electric propulsion on water." In addition to supporting near-term production, Octillion's close proximity and embedded technical collaboration introduce a new phase in Vision Marine's development strategy. By aligning with a team that has delivered over 2 million battery systems globally, Vision Marine is now embracing a more agile, partner-integrated model of innovation, leveraging Octillion's energy systems expertise to guide refinements and influence the evolution of future battery architectures. The battery systems being manufactured by Octillion are integrated with Vision Marine's patent-pending proprietary high-voltage marine propulsion powertrain -the first battery pack purpose-built for electric marine propulsion. Engineered to meet the demanding conditions of marine use, these packs deliver enhanced energy density, ruggedness, and integration simplicity-promoting optimal performance across a wide range of recreational and commercial applications. The packs will be available exclusively with the E-Motion™ 180E outboard and offered as part of a fully integrated, plug-and-play powertrain solution. Designed for rapid OEM adoption and simplified factory installation, this system addresses long-standing industry barriers to electric adoption-namely cost, complexity, and limited performance. By leveraging Octillion's Nevada-based production infrastructure and forward-leaning technical engagement, Vision Marine becomes the first company in North America offering a fully industrialized, high-voltage electric marine outboard system with a U.S.-sourced battery solution -positioning the Company to meet growing demand for electrified boating while supporting regulatory and content compliance initiatives. With domestic battery sourcing secured, enhanced pack performance, and ongoing collaboration with Octillion's technical team, Vision Marine enters the second half of 2025 with the foundation to scale its go-to-market operations and accelerate its innovation agenda. As the Company advances, it remains committed to shaping the future of marine electrification by embracing cross-functional partnerships and leading-edge development models to bring next-generation technologies to the water. About Octillion Power SystemsOctillion Power Systems is a U.S.-based global provider of advanced lithium-ion battery solutions for electric mobility and stationary energy storage. With over 2 million battery packs shipped worldwide, Octillion specializes in scalable, safe, and high-performance battery packs for transportation, industrial, and grid-connected applications. Visit to learn more. About Vision Marine Technologies Marine Technologies Inc. (NASDAQ:VMAR) is a pioneer in marine electrification. Its flagship E-Motion™ 180E system is a fully integrated high-voltage electric outboard powertrain built for OEM adoption at scale. Vision Marine designs and manufactures electric propulsion systems and boats to transform recreational and commercial boating into a zero-emission experience. Learn more at Forward-Looking StatementsCertain statements in this press release constitute "forward-looking statements." These statements include, but are not limited to, expectations regarding the benefits of the new patent, its impact on future product development and original equipment manufacturer integrations, and Vision Marine's competitive position. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect results are discussed in the Company's filings with the Securities and Exchange Commission. Vision Marine undertakes no obligation to update any forward-looking statements except as required by law. Investor & Company ContactVision Marine TechnologiesBruce Nurse - Investor Relations(303) 919-2913bn@ Website: @marine_visionFacebook: @VisionMarineTechnologiesInstagram: @ @VisionMarineTechnologies SOURCE: Vision Marine Technologies Inc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
